Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01338857 · ClinicalTrials.gov registry record · Phase 2
Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01338857 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 12 participants.
The verdict
NCT01338857, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a drug called sorafenib can shrink LGA tumors (low-grade astrocytomas) in children and adults. Previous research has given us a better understanding of this type of tumor by studying the genetic "make-up" of LGAs. From this research, the investigators found that a drug called sorafenib may stop the growth of tumor cells by blocking some of the molecules needed for cell growth and by blocking blood flow to the tumor. This trial is studying how well sorafenib works in treating patients with LGAs, and how the effects relate to the specific genetic "make-up" of your particular tumor. This testing of your tumor's genetic make-up is optional and requires available tumor tissue for testing. In summary, the aims of this study are: To see if sorafenib can shrink LGAs; how well sorafenib is tolerated in patients with LGAs; and, how the effects of sorafenib relate to the genetic make-up of individual LGAs (Optional Study)
Interventions
- DRUG Sorafenib (Nexavar)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01338857
The ClinicalTrials.gov registry entry for NCT01338857 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib (Nexavar) is the first listed.
NCT01338857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01338857 about?
NCT01338857 is a clinical study titled "Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas". The purpose of this study is to determine if a drug called sorafenib can shrink LGA tumors (low-grade astrocytomas) in children and adults. Previous research has given us a better understanding of this type of tumor by studying the genetic "make-up" of LGAs. From this research, the investigators fou...
What is the current status of trial NCT01338857?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2011-04. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01338857?
The interventions under investigation include: Sorafenib (Nexavar) (DRUG).
Who is sponsoring clinical trial NCT01338857?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.